Drug intelligence / Profile preview

anti-miR-10b antagomir

Development stage
Preclinical
Lead developer
TransCode Therapeutics
Modality
Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous
01

Overview

Anti-miR-10b antagomir is a chemically modified antisense oligonucleotide designed to inhibit the oncogenic microRNA-10b (miR-10b). miR-10b is significantly upregulated in high-grade gliomas, including glioblastoma multiforme (GBM), and is associated with poor patient prognosis. It plays a critical role in promoting tumor cell migration, invasion, and the maintenance of glioblastoma stem cells. The antagomir typically consists of a 2-O-methyl-modified RNA sequence that is perfectly complementary to miR-10b and often conjugated to cholesterol to enhance cellular uptake and stability. By sequestering miR-10b, the antagomir restores the expression of downstream tumor suppressor targets, thereby inhibiting the invasive phenotype of GBM cells and reducing tumor growth in preclinical models.

Other names
miR-10b antagomirmiR10b antagomirmiR 10b antagomirantagomir-10bantagomir10bantagomir 10banti-microRNA-10b antagomiranti-microRNA10b antagomiranti-microRNA 10b antagomir
02

Targets

miR-10b (MicroRNA 10b)

Beyond the preview

Go deeper on anti-miR-10b antagomir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-miR-10b antagomir.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call